Day: March 30, 2026

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held March 27-31, 2026, in Denver, CO. The data presented included encouraging signals of clinical activity across multiple measures, with higher rates of complete remission, target ulcer closure, and reductions in ulcer volume, as well as a positive safety profile. The presentation, entitled “Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo...

NEURONES: Declaration of transactions on treasury shares (March 23 to 27, 2026)

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Nanterre, March 30, 2026 Declaration of transactions on treasury shares(period from 23 to 27 March 2026) As part of the share buyback program authorized by the General Meeting of June 5, 2025 and entrusted to CIC, NEURONES made the following purchases between March 23 and 27, 2026 (ISIN code FR0004050250):Day Total daily volume(in number of shares) Weighted average price(unit daily)03/23/2026 46,392 34.13 €03/24/2026 42,993 33.47 €03/25/2026 11,665 34.58 €03/26/2026 7,166 34.26 €03/27/2026 6,805 34.43 €Total 115,021 As of March 27, 2026, excluding the liquidity contract, NEURONES now holds 230,861 of the 24,328,716 shares comprising the company’s capital (i.e., 0.95%). All press releases relating to the share buyback program are published in the “Regulated Information” section (under “Weekly...

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Alignment reached on key elements of ATH434 Phase 3 development program MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements...

Vireo Growth Inc. Announces Update on Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro

Written by Customer Service on March 30, 2026. Posted in Mergers And Acquisitions.

Planned share-based transaction is expected to be completed during the second quarter of 2026 Vireo plans to appoint ScottsMiracle-Gro EVP Chris Hagedorn to its Board of Directors MINNEAPOLIS, March 30, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”) today announced an update on its previously announced nonbinding Memorandum of Understanding (“MOU”) with The Scotts Miracle-Gro Company (“ScottsMiracle-Gro”) to acquire The Hawthorne Gardening Company LLC (including certain of its subsidiaries, “Hawthorne”), an operating subsidiary of ScottsMiracle-Gro and leading provider of nutrients, lighting and other materials used for indoor and hydroponic gardening in North America (the “Hawthorne Transaction”). The Hawthorne Transaction could close any time following five (5) business...

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “2025 has been a year of focused execution across our clinical portfolio, with significant progress in trial enrollment, highlighted by the acceleration of our global Phase...

USA Rare Earth Reports Fourth Quarter and Full-Year 2025 Financial Results

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

STILLWATER, Okla., March 30, 2026 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), an emerging global leader in rare earths, today announced its financial and operational results for the fourth quarter and year ended December 31, 2025. Executive Commentary “2025 was the year that USA Rare Earth set the foundation to execute our integrated rare earth growth strategy,” said Barbara Humpton, CEO of USA Rare Earth. “We acquired the unique and internationally well-known metal and alloy making asset Less Common Metals, and we accelerated our progress toward mining development and magnet manufacturing. We are now rapidly developing a leading, globally integrated rare earth value chain that spans mining, processing, metal-making and magnet manufacturing, for the benefit of the U.S. and our allies. We are also attracting...

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter and year ended December 31, 2025. “The fourth quarter capped a year of important progress for PDS Biotech, marked by meaningful advances across our clinical programs, financial discipline, and intellectual property portfolio,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “Building on the...

Terrestrial Energy Announces Fourth Quarter and Full Year 2025 Results

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

Texas A&M University selected commercial IMSR plant for deployment at RELLIS campus U.S. Department of Energy selected both Terrestrial Energy reactor pilot and fuel-line pilot projects for advanced reactor programs NRC Accepted IMSR Principal Design Criteria Including Inherent Reactor Control Mechanisms Completed business combination, raising approximately $292 million in gross proceeds CHARLOTTE, N.C., March 30, 2026 (GLOBE NEWSWIRE) — Terrestrial Energy Inc. (NASDAQ: IMSR) (“Terrestrial Energy” or “the Company”), a developer of small modular nuclear power plants using its Generation IV Integral Molten Salt Reactor (IMSR) technology, today announced its financial results for the fourth quarter and full year ended December 31, 2025. “The Company made strong progress in 2025 in key areas, regulatory readiness, fuel supply...

BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025

Written by Customer Service on March 30, 2026. Posted in Earnings Releases And Operating Results.

The Company continues its progression towards a Nasdaq uplisting POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has filed its audited consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2025. The financial statements are available for review in their entirety on the OTC Markets website here. With the publication of the audited consolidated financial statements, BioStem has taken another significant step toward a Nasdaq uplisting. “We are pleased to have published our audited financial statements for 2024 and 2025, which marks an important milestone for the Company. Along with...

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Written by Customer Service on March 30, 2026. Posted in Public Companies.

Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs. Vetbiolix, Can-Fite’s veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals. The randomized, double-blind, placebo-controlled, dose-ranging Phase 2 clinical study is evaluating 118 client-owned dogs with osteoarthritis treated with Piclidenoson over...

Day: March 30, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals